Cancer Research Meeting Calendar Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wirth, T.
Right arrow Articles by Kubicka, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wirth, T.
Right arrow Articles by Kubicka, S.
[Cancer Research 65, 7393-7402, August 15, 2005]
© 2005 American Association for Cancer Research

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Telomerase-Dependent Virotherapy Overcomes Resistance of Hepatocellular Carcinomas against Chemotherapy and Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand by Elimination of Mcl-1

Thomas Wirth, Florian Kühnel, Bettina Fleischmann-Mundt, Norman Woller, Meta Djojosubroto, Karl Lenhard Rudolph, Michael Manns, Lars Zender and Stefan Kubicka

Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany

Requests for reprints: Stefan Kubicka, Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Carl Neuberg Str. 1, 30625 Hannover, Germany; E-mail: Kubicka.Stefan{at}mh-hannover.de.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Hepatocellular carcinomas (HCC) are drug-resistant tumors that frequently possess high telomerase activity. It was therefore the aim of our study to investigate the potential of telomerase-dependent virotherapy in multimodal treatment of HCC. In contrast to normal liver, HCC xenografts showed high telomerase activity, resulting in tumor-restricted expression of E1A by a telomerase-dependent replicating adenovirus (hTERT-Ad). Neither tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) or chemotherapy alone nor the combined treatment with both agents resulted in significant destruction of HCC cells. Application of hTERT-Ad at low titers was also not capable to destroy HCC cells, but telomerase-dependent virotherapy overcame the resistance of HCC against TRAIL and chemotherapy. The synergistic effects are explained by a strong down-regulation of Mcl-1 expression through hTERT-Ad that sensitizes HCC for TRAIL- and chemotherapy-mediated apoptosis. To investigate whether down-regulation of Mcl-1 alone is sufficient to explain synergistic effects observed with virotherapy, Mcl-1 expression was inhibited by RNA interference. Treatment with Mcl-1-siRNA significantly enhanced caspase-3 activity after chemotherapy and TRAIL application, confirming that elimination of Mcl-1 is responsible for the drug sensitization by hTERT-Ad. Consistent with these results, heterologous overexpression of Mcl-1 significantly reduced the sensitization of hTERT-Ad transduced cells against apoptosis-inducing agents. Chemotherapy did not interfere with quantitative hTERT-Ad production in HCC cells. Whereas hTERT-Ad virotherapy alone was only capable to inhibit the growth of Hep3B xenografts, virochemotherapy resulted in vast destruction of the drug-resistant HCC. In conclusion our data indicate that telomerase-dependent virotherapy is an attractive strategy to overcome the natural resistance of HCC against anticancer drugs by elimination of Mcl-1.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Hepatocellular carcinoma (HCC) is one of the main complications of liver cirrhosis and a serious health problem worldwide with rising incidences particularly in the western world (1). HCCs are usually treated by surgical resection or liver transplantation with curative options for the patients when the disease is caught at an early stage (2). However, ~70% of patients diagnosed are inoperable because of advanced tumor growth or liver cirrhosis. Percutaneous ethanol injection (PEI) and radiofrequency or laser thermal ablation are minimally invasive techniques providing a curative potential for patients with liver cirrhosis and small nodular-type tumors. Nonrandomized studies have shown that PEI produces prognoses similar to surgical resection.

Patients with HCCs that cannot be completely removed by surgery or ablated by minimal invasive approaches have a dismal prognosis, as HCCs belong to the group of cancers that are resistant to systemic chemotherapy. Most of the patients with HCCs die due to intrahepatic tumor growth rather than extrahepatic metastases (3), which is considered as a rationale for regional intra-arterial therapy. But even intra-arterial chemoembolization provides, if at all, only a small survival advantage for patients as shown in randomized phase III studies (4, 5). Therefore, more effective approaches for the treatment of HCCs are urgently needed.

Gene therapy with viral vectors such as adenoviruses may be an attractive tool to treat HCCs. Recently, we showed that replacement of p53 by intra-arterial adenoviral gene therapy was capable to induce tumor remissions in p53 mutated HCCs in the liver of rats and improved the survival of the animals (6). However, gene therapy strategies using nonreplicating adenoviral vectors have some limitations for clinical application because of the ineffective transduction rate of cancer cells. Principally, replicating vectors have the potential to overcome the hurdle of ineffective tumor transduction by lysis of infected cancer cells and spreading of the infection throughout the whole tumor mass. Tumor-specific replicating adenoviral vectors can be generated by deletion or mutation of viral genes (7, 8), tumor-specific recombination of viruses (9), transcriptional repression of cellular genes essential for viral replication (10), and by transcriptional control of viral genes by tumor-specific promoters (11–13).

Conditionally replicating adenoviruses have been constructed for the treatment of HCCs by using AFP-promoter controlled viral gene expression (12, 14, 15). However, only in 30% of patients with HCCs the {alpha}-fetoprotein (AFP) serum level is elevated above 400 ng/mL (3) and even in tumors with high AFP serum levels the activity of the AFP promoter may be heterogenous within the tumor tissue resulting in ineffective spreading of AFP-promoter controlled viruses. A more promising approach for the construction of tumor-specific replicating vectors seems the linkage of viral replication to frequently activated oncogenic pathways. Reactivation of telomerase activity is a characteristic molecular mechanism in hepatocarcinogenesis and it has been shown that hTERT is overexpressed in ~80% to 100% of human HCCs (16–18). We and others recently showed that the hTERT-promoter can be used to generate tumor-specific replicating vectors for safe and effective virotherapy of telomerase-positive cancers (19–28). The resulting adenoviral vector hTERT-Ad contained the E1A protein under the control of the hTERT promoter thus restricting its replication to telomerase-positive cells.

It was therefore the aim of this study to investigate the value of hTERT-Ad in virotherapy of HCCs and to develop effective antitumor strategies based on virotherapy in conjunction with chemotherapy and tumor necrosis factor–related apoptosis-inducing ligand (TRAIL). In contrast to normal liver, all investigated HCCs had high telomerase activity, resulting in tumor-restricted expression of E1A by hTERT-Ad. Chemotherapy interfered neither with adenoviral replication in HCCs nor with the quantitative production of the adenoviral vector, which are important preconditions for an effective simultaneous virochemotherapy. Treatment of HCC cells with low titers of hTERT-Ad overcame the resistance of the tumor cells against chemotherapy and TRAIL by down-regulating Mcl-1 expression. Whereas hTERT-Ad virotherapy alone was only capable to inhibit the growth of HCCs, the combination of systemic chemotherapy and local hTERT-Ad virotherapy showed strong synergistic effects in vivo, resulting in significant tumor remission. Our data indicate that virochemotherapy may be an attractive strategy for the treatment of drug-resistant tumors, such as HCCs.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Cell lines, plasmids, and adenoviral vector preparation. The human cell lines Hep3B, Huh7 (both hepatoma), AGS (gastric carcinoma), HT1080 (fibrosarcoma), and the embryonal kidney cell line 293 were obtained from American Type Culture Collection (Manassas, VA). The cells were maintained in growth medium (DMEM + Glutamax; Life Technologies, Inc., Gaithersburg, MD) supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies), 100 units/mL penicillin, and 100 g/mL streptomycin (Seromed, Berlin, Germany) at 37°C in 5% CO2. CaCo cells were maintained in 20% fetal bovine serum containing medium. The Mcl-1 expression plasmid pcDNA3.V5-Mcl-1 was kindly provided by Prof. Dr. Roland Schmid (München, Germany). Construction and characterization of hTERT-Ad as well as adenoviral vector preparation have been described previously (22).

Telomerase extract preparation and telomerase repeat amplification protocol assay. Telomerase extract preparation and telomerase repeat amplification protocol (TRAP) assays were done with the TRAPeze Telomerase Detection System (Chemicon, Temecula, CA) according to the manufacturer's recommendations. Briefly, a small portion (~2 mm3) of liver/tumor tissue was minced in ice-cold PBS. After washing with PBS, tissue samples were incubated in 200 µL CHAPS lysis buffer containing 200 units/mL RNase inhibitor (Sigma, St. Louis, MO) for 30 minutes on ice and centrifuged at 15,000 rpm for 20 minutes at 4°C. The resulting supernatant (200 ng) was used for the TRAP Assay. Protein concentration determination was done using Micro BCA Protein Assay Kit (Pierce, Rockford, IL). The tumor cell extract provided by the manufacturer was used as a positive control, and the heat-inactivated extract of the same batch was used as a negative control. TRAP mixtures were subjected to telomerase extension at 30°C for 30 minutes and then to PCR amplification in the presence of TS primer labeled with 32P-{gamma}ATP (Amersham Biosciences, Freiburg, Germany). PCR was done with an initial denaturation (94°C, 30 seconds) followed by denaturation (94°C, 30 seconds) and annealing extension step (60°C, 30 seconds) for 27 cycles, and final incubation at 4°C. TRAP products were size fractionated on a 16% polyacrylamide gel. The gel was dried at 75°C and then exposed to Hyperfilm MP (Amersham Biosciences) at –80°C for 12 hours.

Western blot analysis. For protein extract preparation Huh7 and Hep3B cells were harvested and subsequently lysed with radioimmunoprecipitation assay (RIPA) buffer [1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, and 0.02% protease inhibitor cocktail (Sigma), in PBS]. For analysis of transduced HCC tumors in vivo, 1 x 107 cells were inoculated s.c. in nude mice and tumors with an approximate volume of 500 mm3 were injected with 1 x 109 viral particles of Ad-GFP, hTERT-Ad, or Ad-wt, respectively. Tumors were harvested 24 hours after injection. For murine liver tissue analysis, 1 x 109 viral particles were injected i.v. into nude mice and mice livers were harvested after 24 hours. Tissue samples were homogenized in RIPA buffer using a Potter-Elvehjem homogenizer. After centrifugation the supernatant was obtained and the protein concentration was determined by Bio-Rad protein assay (Bio-Rad, Richmond, CA). Proteins (10-40 µg) were separated on a 10% SDS polyacrylamide gel and electrotransferred to a HyBond N-membrane (Millipore, Eschborn, Germany). Equal loading and extract quality were controlled by Coomassie staining and analysis of actin expression. Primary antibodies for protein detection were rabbit anti-Ad2-E1A-13S-5 (sc-430; Santa Cruz Biotechnology, Santa Cruz, CA) for E1A, mouse anti-bcl-2 human/mouse (Calbiochem, La Jolla, CA) for Bcl-2, rabbit anti-bcl-XS/L-(S18) (sc-634, Santa Cruz Biotechnology) for Bcl-XL, rabbit anti-human/mouse TRAIL-R2/DR5 (AF 837, R&D Systems, Wiesbaden, Germany) for DR5, rabbit anti-MCL-1 (AAP-240, Stressgen, San Diego, CA) for Mcl-1, and goat anti-actin-(C-11) (sc-1615, Santa Cruz Biotechnology) for actin. As secondary antibodies, the following horseradish peroxidase–conjugated antibodies were used: donkey anti-mouse IgG (Dianova, Hamburg, Germany), donkey anti-rabbit IgG (Dianova), and mouse/human absorbed anti-goat (sc-2056, Santa Cruz Biotechnology). Antigen-antibody complexes were visualized using the enhanced chemiluminescence detection system as recommended by the manufacturer (Amersham Biosciences).

Chemosensitivity assessment and cytolysis assays in vitro. Cells were seeded at 1 x 105 cells/cm2 density in 24-well plates. For initial analysis of sensitivity to chemotherapy, HCC cells were exposed to doxorubicin (50 to 400 ng/mL) or 5-fluorouracil (1 to 20 µg/mL) in medium. After 48 hours, crystal violet staining was done to visualize cell destruction. Cell layers were rinsed with PBS and fixed for 10 minutes with 10% formalin in PBS. Cells were washed with distilled water and stained for 30 minutes with 0.1% crystal violet in 10% ethanol.

For the cytolysis assays, cells were seeded at 1 x 105 cells/cm2 density in 24-well plates and infected with low multiplicity of infection (MOI) of 0.1 for Huh7 and 0.01 for Hep3B. After 4 days of incubation, 1 mL of chemotherapeutic agents in medium was added in low concentrations [doxorubicin, 50 ng/mL; cisplatin, 0.5 µg/mL; 5-fluorouracil, 5-FU, 5 µg/mL]. For TRAIL experiments, either recombinant human soluble TRAIL (KillerTRAIL, AXXORA, Grünberg, Germany) in concentrations of 50 ng/mL or Ad-TRAIL was added after 4 days in nontoxic MOIs (1-10) for Huh7 and 1 for Hep3B. After addition of chemotherapy, Ad-TRAIL or the combination of both, the cells were further incubated for 2 to 4 days. Cell layers were then stained with crystal violet to visualize cytolysis.

Small interfering RNA experiments and caspase assays. For small interfering RNA (siRNA)–mediated down-regulation of Mcl-1 the following siRNA sequences were purchased from MWG Biotech (Ebersberg, Germany): 5'-GGUCGGGGAAUCUGGUAAUdTdT-3' as sense and 5'-AUUACCAGAUUCCCCGACCdTdT-3' as antisense strand for the first siRNA duplex and sense strand 5'-GAAACGCGGUAAUCGGACUdTdT-3' and antisense strand 5-AGUCCGAUUACCGCGUUUCdTdT-3' for the second siRNA duplex. For Western blot analysis of Mcl-1 down-regulation and caspase assays 2 x 105 cells were seeded in 6-cm dishes at a confluency of ~20%. Cells were transfected twice with 500 pmol of Mcl-1 or scrambled siRNA using Oligofectamine (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. After 24 hours, the cells were then harvested for Western blot analysis. Twenty-four hours after the second siRNA transfection, cells were incubated with doxorubicin (3 mL of 200 ng/mL) or infected with Ad-TRAIL (MOI 5) and harvested after a further incubation for 24 hours. For caspase assays a slightly modified Caspase-3 assay from BD Biosciences (BD ApoAlert Caspase Fluorescent Assay Kit; Heidelberg, Germany) was used. Cells were washed once with PBS, lysed with 200 µL of lysis buffer supplied by the manufacturer, and were then subjected to five cycles of freezing and thawing. Ten microliters of native protein extracts were measured with or without caspase inhibitor. Samples were incubated for 2 hours at 37°C and fluorescence was detected after 1 and 2 hours using a standard fluorometer. Protein concentration in extracts was measured by Bio-Rad protein assay (Bio-Rad) and fluorescence of each sample was normalized against protein content. The results were processed by using Student's t test, with P < 0.05 accepted as denoting statistical significance.

Mcl-1 complementation experiments. The day before transfection a total of 7 x 105 Huh 7 cells per well were seeded in 6-well plates and grown to subconfluency. Transfection was done with LipofectAMINE 2000 (Invitrogen) according to the manufacturer's protocol. Four micrograms DNA per well (1 µg pcDNA3.V5-Mcl-1, 0.3 µg pCMV-GFP, and 2.7 µg pBluescript or 1.3 µg pCMV-GFP and 2.7 µg pBluescript for corresponding controls) were transfected at a DNA/LipofectAMINE ratio of 1:2.2. The transfection was carried out for 4 hours and complexes were removed by PBS washing and medium exchange. The cells were then treated with the following agents if indicated in the figures: 1 hour after transfection (medium exchange) the cells were infected with hTERT-Ad at an MOI of 1. Twelve hours later, doxorubicin was added at a final concentration of 200 ng/mL and further 8 hours later Ad-TRAIL was added at an MOI of 0.3. This time schedule was chosen to synchronize optimal caspase-3 activity induced by Ad-TRAIL or doxorubicin with physiologic down-regulation of Mcl-1 caused by hTERT-Ad. Cells were harvested in parallel 43 hours after transfection for the preparation of cellular extracts. Mcl-1 and actin Western blots and caspase-3 activity measurements were done according to the methods described above. Protein content was determined using the Bio-Rad protein assay.

Quantitative analysis of viral replication. For measurement of viral replication in tumor cells and supernatants, 2 x 105 cells were seeded in 6-well plates and infected with an MOI of 5. To examine the effect of chemotherapy on viral replication, one group was additionally supplied with 100 ng of doxorubicin. At the time points indicated in the figures, 1 mL of the supernatant was removed and stored at –20°C. Infected cells were harvested by scraping off in the remaining medium, centrifuged at 500 x g for 5 minutes and the supernatant was discarded. The cell pellet was then washed twice with PBS and resuspended in PBS. After four cycles of freezing and thawing, 100 µL of cell lysate or the corresponding supernatant were analyzed for viral particles using the TCID50 method. For this purpose, 293 cells were seeded in 96-well plates (104 cells per well). The next day, eight serial 10-fold dilutions of the virus containing samples were subjected to the 96-well plate (100 µL per well). After 14 days of incubation, the observable cytopathic effects per dilution were counted, and the ratio between lyzed and intact wells was determined. The titer was calculated using the equation T (infective particles/mL) = 10sum of ratios + 0.5. Viral titers were further confirmed using the Rapid Titer Kit (BD Biosciences) according to the manufacturer's protocol.

Detection of viral infection via duplex PCR. Infection of different organs was detected with PCR for either adenoviral fiber DNA or duplex PCR for murine caspase-8 and adenoviral fiber DNA. For duplex PCR, the use of the two primer pairs for viral and genomic DNA allowed semiquantitative comparison of transduced cells with total number of harvested cells. For this purpose, organs from mice infected i.v. with 1 x 109 PFU of hTERT-Ad were harvested 8 hours after infection. Fifty-milligram portions of tissue were digested in a mixture of 750 µL solution A [50 mmol/L Tris (pH 8.0), 100 mmol/L EDTA, 100 mmol/L NaCl, 1% SDS] and 50 µL Proteinase K (22 mg/mL, Roche Diagnostics, Mannheim, Germany) by overnight shaking at 56°C. Cell debris was pelleted in a tabletop centrifuge and DNA in the supernatant was isolated by conventional isopropanol precipitation. The DNA was resolved in TE 8.0/RNase by shaking for 2 hours at 37°C and diluted in a final concentration of 50 ng/µL. Adenoviral infection was determined using the primer pair fiber-fw (5'-CCCAAAATGTAACCACTGTGAGC-3') and fiber-rev (5'-GTGTTTAGGTCGTCTGTTACATGC-3') directed against the coding sequence of the fiber protein of adenovirus serotype 5, resulting in a 417-bp fragment. For duplex PCR, mouse genome templates as control were determined using the primers Intr2-s (5'-CCAGATGTATCTCTGTGCGTTTGC-3') and Exon3-as (5'-GTTATTTTCTGCCAGCATGGTCC-3'), directed against the murine locus of caspase-8 (intron 2/exon 3) resulting in a 520-bp fragment. PCR was done using the HotStarTaq Master Mix (Qiagen, Hilden, Germany), 50 ng DNA and murine genomic primers at a concentration of 400 nmol/L each. The duplex PCR reaction was started as follows: 15 minutes at 95°C; [30 seconds at 94°C; 30 seconds at 57°C; 1 minutes at 72°C] x 3. The reaction was interrupted, fiber primers were added (same concentration) and further 27 cycles were done. For single PCR against adenoviral fiber DNA, 30 cycles with the conditions mentioned above were done. Products of both PCRs were resolved on a 1.5% agarose gel.

Animal experiments and in vivo monitoring of viral replication. Pathogen-free male NMRI nu/nu mice (age 6-8 weeks) were obtained from the Animal Research Institute of the Medizinische Hochschule Hannover. All animal experiments were done according to the German legal requirements. Tumor xenografts were established by s.c. injection of 1 x 107 cells into both flanks of mice. For infection experiments, adenoviruses were prepared, purified, and titered as described above. Before infection the virus was dialyzed twice against a solution containing 10 mmol/L Tris (pH 8.0), 1 mmol/L MgCl2, and 140 mmol/L NaCl at 4°C. Tumor nodules were grown to a size of ~400 mm3 before infection. For combination therapy, mice received 10 µg of doxorubicin i.v. twice a week. Infection with hTERT-Ad and Ad-GFP, respectively, was done on day 0, 7, and 14 with 1 x 109 pfu in 200 µL for each injection. Additional infection with Ad-TRAIL (1 x 109 viral particles) was done on days 3, 11, and 17. For statistical tumor growth assessment, infected tumors were measured in size twice a week using a digital caliper. Tumor volume was calculated using the following equation: V (tumor) = (length x width2) / 2. For each group six animals (= 12 tumors) were assessed. The difference in mean tumor volume between treatment groups was compared for statistical significance using the unpaired, two-tailed t test with P < 0.05 accepted as denoting statistical significance.

For immunohistochemical analysis, tumor nodules were harvested at day 20, embedded in TissueTec (Sakura, Zoeterwonde, the Netherlands) and shock-frozen in liquid nitrogen. Slices (7 µm) were prepared from cryopreserved tumor specimen and fixed in 4% paraformaldehyde in PBS. For histologic investigation, the slices were stained with H&E according to standard procedures. Viral replication was detected by treating the slices with a goat anti-hexon antibody (20-AG02, Fitzgerald, Concord, MA), diluted 1:100 in 20% FCS/PBS. As secondary antibody, a Cy3-conjugated rabbit anti-goat antibody (C-2821, Sigma) in a dilution of 1:100 was used and positive cells were detected by fluorescence microscopy.

Assessment of liver damage and stem cell toxicity. For detection of liver damage in the setup of tumor therapy with hTERT-Ad, chemotherapy or TRAIL or combinations thereof, blood samples were taken from the mice at the end of the in vivo experiment (day 20, see above). The blood samples were centrifuged for 20 minutes at 4,000 x g and 4°C. Serum was then transferred to separate tubes and measured for transaminase activity [aspartate aminotransferase (AST) and alanine aminotransferase (ALT)]. For assessment of stem cell toxicity, 20 µL of whole blood samples were taken on day 20 and measured for the content of hemoglobin, leukocytes, and platelets. To simulate systemic adenoviral infection after local intratumoral injection, a group of five mice was included that received i.v. injections of 0.5 x 108 plaque-forming unit (pfu)/g body weight hTERT-Ad instead of intratumoral injections.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Specific expression of E1A in telomerase-positive hepatocellular carcinomas by hTERT-Ad. To investigate the activity of telomerase in normal liver and in HCCs, we did TRAP assays in specimen of liver tissues and in tumor tissue derived from HCC cell lines. The TRAP assays showed high telomerase activity in all HCC cell lines investigated (data not shown) as well as in their s.c. implanted tumor equivalents in vivo (Fig. 1). In contrast, normal human liver was negative for telomerase activity thus providing obligatory preconditions required for telomerase-dependent tumor virotherapy. Murine liver showed detectable levels of telomerase activity but substantially lower than the human HCC cells examined. We therefore investigated the expression of E1A by hTERT-Ad in murine liver and s.c. growing HCCs 24 hours after viral transduction. In accordance with the telomerase activity findings, infection studies of hTERT-Ad in vivo revealed effective, tumor-restricted expression of E1A without E1A expression in liver tissue (Fig. 2). Despite the low telomerase activity observed in murine liver, indicating a low transcriptional activity of the mTERT promoter, regulation of E1A expression by the hTERT promoter in hTERT-Ad did not result in detectable E1A expression in murine liver.



View larger version (42K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. Human hepatoma cell derived tumor tissue shows high telomerase activity compared with human liver tissue. Huh7, HepG2, and Hep3B cells were implanted on nude mice and grown to a size of 1.5 cm3. Tumors were then harvested for protein extraction and subsequent telomerase activity measurements were done. Tumor extracts were compared with extracts from both murine and human liver tissue. Positive and negative controls were included according to the manufacturer's protocol.

 


View larger version (32K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2. E1A is absent in mouse liver following infection with hTERT-Ad but is highly expressed in infected tumor tissue derived from human hepatoma cells; 0.5 x 108 pfu/g of hTERT-Ad, Ad-wt, and Ad-GFP were injected i.v. into nude mice. Twenty-four hours later, livers were harvested for protein extract preparation. The E1A level was determined by Western blot (top) and equal loading was controlled by a corresponding ß-actin blot (bottom). For the determination of E1A expression levels in infected tumor tissue, tumors derived from Huh7 and Hep3B cells were s.c. established and infected intratumorally as described above. After 24 hours, the tumor tissues were harvested for protein extraction and subsequent Western blot analyses.

 
Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against tumor necrosis factor–related apoptosis-inducing ligand and chemotherapy. HCCs are resistant to chemotherapy- and TRAIL-mediated apoptosis. Recently, it has been shown that chemotherapy agents augment TRAIL-induced apoptosis in human HCC cell lines (29), suggesting multimodal strategies for the treatment of HCCs. Therefore, we investigated the influence of hTERT-Ad-virotherapy on chemotherapy- and TRAIL-mediated apoptosis of HCC cells. First we assessed the susceptibility of Huh7 and Hep3B cells to chemotherapy by incubating confluent cell layers with increasing concentrations of doxorubicin or 5-FU for 48 hours. In contrast to fibrosarcoma (HT 1080) and gastric carcinoma (AGS) cell lines, HCC cells were nearly resistant to chemotherapy (Fig. 3A).



View larger version (116K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3. Telomerase-dependent virotherapy sensitizes human HCC cells to standard chemotherapeutic agents and TRAIL. A, confluent cell layers of hepatoma cells (Huh7 and Hep3B) and nonhepatic cell lines (HT1080 and AGS) were treated with increasing concentrations of doxorubicin or 5-FU as indicated. Forty-eight hours later, crystal violet staining of the cell layers showed that hepatoma cells are resistant even to high doses of standard chemotherapy. B, confluent cell layers of Hep3B and Huh7 hepatoma cells were infected with adenoviral vectors (MOI 0.1 for Huh7 and 0.01 for Hep3B) and subsequently treated with low concentrations of doxorubicin, cisplatin, or 5-FU, respectively. Crystal violet–stained cytolysis assays showed a strong sensitization of hepatoma cells against chemotherapeutics. C, confluent cell layers of Hep3B and Huh7 were infected as described above. TRAIL administration by infection with Ad-TRAIL revealed synergistic effects to virotherapy, which could be further enhanced with standard chemotherapy.

 
Next we incubated Hep3B and Huh7 HCC cells with low titers of an E1-deleted adenoviral vector (Ad-GFP) or with replicating adenoviruses (Ad-wt, hTERT-Ad) and the cells were subsequently treated with different chemotherapeutic agents as indicated in Fig. 3B. Adenoviruses applied at a MOI of 0.01 to 0.1 were not capable to destroy the cell layer of HCC cells, as visualized by crystal violet staining. In contrast to application of the E1-deleted Ad-GFP, both Ad-wt and hTERT-Ad were capable to overcome the resistance of Hep3B and Huh7 cells to doxorubicin, cisplatin, and 5-fluorouracil and resulted in almost complete disruption of the cell layers (Fig. 3B). Similar results were obtained when HCC cell lines were exposed to TRAIL to induce apoptosis. Only the E1-expressing adenoviruses Ad-wt and hTERT-Ad strongly sensitized Hep3B and Huh7 cells to apoptosis, induced by either Ad-TRAIL (Fig. 3C) or recombinant TRAIL (50 ng/mL, data not shown). In contrast, infection with Ad-GFP before TRAIL treatment did not result in significant cell apoptosis. Additionally, antitumor efficacy could be even further enhanced by employing triple combination therapy including replicative virus, chemotherapy, and TRAIL administration. Interestingly, triple therapy without replication-competent vectors had only little effects on tumor cells confirming the essential contribution of adenoviral E1 expression for strong synergistic effects with apoptosis-inducing agents.

hTERT-Ad down-regulates Mcl-1 expression and sensitizes hepatocellular carcinoma cells for chemotherapy and tumor necrosis factor–related apoptosis-inducing ligand–mediated apoptosis. To explore the molecular mechanism involved in hTERT-Ad-mediated sensitizing for apoptosis, we investigated the expression of members of the Bcl-2 family and TRAIL-DR5 receptor in HCC cells after adenoviral transduction. Whereas Bcl-2, Bcl-xl, and DR5 remained constant after viral infection, Mcl-1 was strongly down-regulated 48 hours after transduction with replication-competent adenoviral vectors (Fig. 4A). In contrast, infection with the replication-deficient vector Ad-GFP did not influence the expression of Mcl-1 indicating that adenoviral infection itself is not sufficient to decrease Mcl-1 expression levels. These results show that the inhibitory effect on Mcl-1 expression is mediated specifically by replicative viruses, probably due to protein expression from the adenoviral E1 region. Consequently, Mcl-1 down-regulation may therefore represent a potential cause for synergistic effects of virochemotherapy as described above. We therefore inhibited Mcl-1 expression by specific siRNA to clarify the relationship between Mcl-1 expression levels and HCC cell responses to chemotherapy- or TRAIL-mediated apoptosis. As shown in Fig. 4B effective down-regulation of Mcl-1 in hepatoma cells was accomplished following transfection of Mcl-1 siRNA compared with untransfected cells or cells transfected with scrambled siRNA. Subsequent caspase-3 assays showed that siRNA mediated inhibition of Mcl-1 resulted in significantly enhanced susceptibility of HCC cells to chemotherapy- or TRAIL-mediated apoptosis (Fig. 4C). Elimination of Mcl-1 proved to be sufficient to overcome the tumor cells' resistance to chemotherapeutic agents and TRAIL. To further confirm the importance of Mcl-1 in susceptibility to apoptosis, complementation experiments were done by heterologous overexpression of Mcl-1. Transfection of an Mcl-1 expression plasmid before hTERT-Ad infection sufficiently restored Mcl-1 protein levels as detected by Western blot analysis (Fig. 4D). Measurement of caspase-3 activity after application of doxorubicin or TRAIL revealed significant reduction of caspase activity when Mcl-1 expression was restored (Fig. 4E). These observations confirmed our hypothesis that the interference of virotherapy with Mcl-1 levels in infected cells represents an important molecular mechanism underlying the synergistic therapeutic effects of virotherapy combined with chemotherapy and/or TRAIL.



View larger version (44K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4. Down-regulation of Mcl-1 in the course of viral replication is responsible for sensitization of hepatoma cells against chemotherapy and/or TRAIL administration. A, human hepatoma cells Huh7 and Hep3B were infected with replication incompetent (Ad-GFP) and replicative adenoviral vectors (hTERT-Ad and Ad-wt) at an MOI of 10 (Huh7) or 1 (Hep3B). Twenty-four and 48 hours following infection, the cell layers were harvested and whole cell lysates were prepared. Western blot analyses were done to compare protein levels of the antiapoptotic proteins Mcl-1, Bcl-2, and Bcl-xl. Additionally, levels of TRAIL receptor DR5 as well as E1A were determined and normalized against ß-actin expression. Expression of Mcl-1 was strongly down-regulated by hTERT-Ad and Ad-wt. B, Huh7 and Hep3B cells were transfected with siRNA duplexes directed against Mcl-1 or were mock transfected with scrambled siRNA. RNA interference–mediated down-regulation of Mcl-1 expression is shown by Western blot in both cell lines. Untransfected cells were used as control without transfection stress. C, cells were then exposed to chemotherapy or TRAIL (by Ad-TRAIL infection) and apoptosis was investigated by caspase-3 activity measurements. *, RNA interference–mediated inhibition of Mcl-1 resulted in significant enhanced caspase-3 activity after chemotherapy and TRAIL administration. D, heterologous expression of Mcl-1 via expression plasmid restored Mcl-1 expression in hTERT-Ad-transduced cells. Huh-7 cells were transfected using a plasmid for expression of Mcl-1 under CMV-promoter control. A GFP expression plasmid was used as control. Cellular extracts were prepared and Mcl-1/actin was detected by Western blot analysis. E, heterologous expression of Mcl-1-reduced apoptosis of Huh-7 cells induced by virochemotherapy or viro-TRAIL therapy. If indicated in the figure, the Mcl-1/GFP transfected cells were treated with hTERT-Ad (MOI 1), doxorubicin (final concentration of 200 ng/mL), and Ad-TRAIL (MOI 0.3). *, Mcl-1 expression resulted in significant reduction of caspase-3 activity.

 
Chemotherapy does neither interfere with adenoviral replication nor with net release of vectors in hepatocellular carcinomas. The outcome of virotherapy depends on a complex balance between viral replication and cytotoxicity (30). If infected tumor cells die prematurely with regard to viral progeny, this can impair the therapeutic effect of hTERT-Ad in HCCs, as an optimized progress of production, release, and spread of viral vectors may be prevented. We therefore assessed the effect of chemotherapy on intracellular virus production and release of viral particles in HCC cells. Interestingly, although hTERT-Ad strongly sensitized HCC cells for chemotherapy-mediated apoptosis, therapeutic concentrations of doxorubicin did not significantly interfere with the course of adenoviral replication within infected Hep3B (Fig. 5) and Huh7 cells (data not shown). In addition, we revealed that the net release of viral particles by infected tumor cells is unchanged in the presence of therapeutic concentrations of doxorubicin, indicating that chemotherapy would not impair hTERT-Ad virotherapy.



View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 5. Application of chemotherapy does neither interfere with adenoviral replication nor with net release of viral particles by infected cells. Hep3B cells were infected with hTERT-Ad or Ad-wt at an MOI of 5. Doxorubicin was applied at a concentration of 100 ng/mL. Following infection, cells and supernatants were separately collected at the time points indicated and investigated for infectious particle content.

 
Telomerase-dependent virotherapy acts strongly synergistic with systemic chemotherapy in vivo without significant side effects to the normal liver. To evaluate the therapeutic potential of virotherapy in HCC using hTERT-Ad in conjunction with chemotherapy and TRAIL, Hep3B-derived s.c. tumor xenografts were established on nude mice. Tumor xenografts were infected thrice with Ad-GFP or hTERT-Ad (1 x 109 pfu), respectively. Subgroups of mice were subjected to either additional administrations of Ad-TRAIL (1 x 109 pfu) thrice in the course of the experiment, or i.v. injections with doxorubicin twice a week, or a combination of these two treatments, respectively. In agreement with the results obtained from cell culture experiments, treatment of HCC with Ad-GFP in combination with either Ad-TRAIL or doxorubicin resulted only in negligible effects on tumor growth (Fig. 6A). Even in the group of animals receiving the combined treatment of Ad-GFP, Ad-TRAIL, and doxorubicin, only a slight retardation of tumor growth could be observed. In contrast, virotherapy by hTERT-Ad alone or the combination of hTERT-Ad with Ad-TRAIL significantly inhibited tumor growth. However, synergistic effects of Ad-TRAIL on hTERT-Ad virotherapy could not be confirmed in these in vivo experiments, which may be explained by the heterogenous Ad-TRAIL distribution within the tumor nodules and the lack of TRAIL activity in some tumor areas. When systemic chemotherapy was combined with virotherapy, strong synergistic effects could be observed in vivo resulting in significant remission of tumors. Again, the coinjection of Ad-TRAIL to the group receiving virochemotherapy only resulted in minor effects on tumor growth curves confirming that the combined approach of virotherapy and Ad-TRAIL was not an effective therapeutic option in vivo.



View larger version (79K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 6. hTERT-Ad virotherapy shows strong synergistic effects in combination with chemotherapy in vivo. A, s.c. Hep3B tumor xenografts on nude mice were infected intratumorally as indicated with nonreplicative (Ad-GFP) or replicative (hTERT-Ad) adenoviral vectors. A subgroup of tumors were treated with TRAIL (intratumoral injection of Ad-TRAIL), systemic administration of doxorubicin or a combination of both agents. Observation of the tumor growth demonstrated strong synergistic effect of virotherapy and chemotherapy resulting in significant (*) tumor remission compared with virotherapy alone. B, histologic examination of the explanted Hep3B tumors with H&E-staining at the end of the experiment showed vast destruction of tumor tissue after virochemotherapy. Representative parts of tumor histologies of the different therapy groups at 100x magnification. C, hexon staining of harvested tumors was done at the end of the experiment (day 20). Replication of hTERT-Ad in border areas between necrosis and healthy tumor tissue was visualized suggesting that viral replication was still proceeding at the end of the experiment.

 
Because a rapidly growing HCC xenograft model in nude mice was used in our in vivo experiments, ineffective removal of necrotic debris may lead to underestimation of the veritable therapeutic efficacy of virotherapy. Therefore, H&E-stained cryosections were done from tumor xenografts when the experiment has been terminated at day 20. As expected from the study of tumor growth curves, cryosections obtained from the groups receiving Ad-GFP with either Ad-TRAIL, doxorubicin, or combined treatment revealed solid tumor architecture without evidence of significant intratumoral necrosis (Fig. 6B). Tumors treated with hTERT-Ad alone or with the combination of hTERT-Ad and Ad-TRAIL showed large necrotic areas distributed throughout the tumor mass. However, in animals receiving the combination of systemic chemotherapy and hTERT-Ad, the therapeutic effect was strongly enhanced resulting in nearly complete destruction of the tumor xenografts.

Because the last intratumoral injection of hTERT-Ad into the tumor xenografts was done 7 days before the experiment was terminated, we were interested in finding out whether viral replication was still persisting at the end of the experiment. To visualize ongoing viral replication, expression of adenoviral hexon protein was investigated in immunostained cryosections. In contrast to groups of animals receiving Ad-GFP, hexon staining in the tumors of mice receiving hTERT-Ad revealed active viral replication even 7 days after the last injection. Replication could be particularly detected in areas separating intact tumor tissue from necrosis suggesting that the viral spreading was still proceeding (Fig. 6C).

Finally, for assessment of liver toxicity in simultaneous virochemotherapy, serum transaminase activity was measured at the end of the in vivo experiment for each of the eight groups examined. For both AST and ALT serum activity, no significant difference was seen between the groups receiving tumor therapy and an untreated control group (Fig. 7A). As hTERT-Ad replication takes place in telomerase-positive cells, potential side effects in stem cells and cells of germ line origin have to be investigated. For this purpose, tissue samples from liver, spleen, testis, epididymis, small intestine, and bone marrow were screened for adenoviral infection with PCR. To simulate systemic infection after intratumoral virus injection, the viral dosis that was usually injected into the tumor was directly injected i.v. As shown in Fig. 7B in comparison with a genomic template, high infection rates could only be seen in liver. When a highly sensitive single PCR against adenoviral DNA was used, liver and spleen displayed detectable viral infection. Murine bone marrow revealed low viral infection, whereas testis, epididymis, and small intestine were negative for viral DNA. To rule out long-term stem cell toxicity, blood samples were examined at the end of the experiments for their content of hemoglobin, leukocytes, and platelets. As shown in Fig. 7C, neither combination treatment of hTERT-Ad, chemotherapy and TRAIL nor the repeated i.v. injection of hTERT-Ad resulted in significant alterations of the hemograms.



View larger version (27K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 7. hTERT-Ad virotherapy after either local or systemic application does not cause detectable side effects. A, blood samples were taken from animals from the in vivo experiment groups (see Fig. 6A) at the end of the experiment (day 20). Liver damage was compared using transaminase measurements for both AST and ALT. B, a NMRI nu/nu mouse was i.v. injected with 0.5 x 108 pfu/g hTERT-Ad. Infection of murine organs was assessed 8 hours after infection using either single PCR against adenoviral DNA or duplex PCR against adenoviral and genomic DNA as an internal control. C, blood samples were taken from animals of the seven different therapy groups (Fig. 6A) as well as from a group that received the hTERT-Ad dosis of 0.5 x 108 pfu/g via i.v. injection. Changes in leukocyte and platelet numbers as well as hemoglobin content were measured at the end of the experiment (day 20) and compared with an untreated control group.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
In our study, we investigated the potential of telomerase-dependent virotherapy in multimodal treatment of HCCs. Telomerase activation is one of the critical steps in malignant transformation and therefore an attractive target for selective cancer therapy. Although telomerase is a complex composed of a catalytic subunit (hTERT) and an RNA component (hTERC), telomerase activity is mainly transcriptionally controlled by the hTERT promoter (31). It has been shown that telomerase is strongly activated in the majority of HCCs and the degree of telomerase activation correlates with histologic dedifferentiation of the tumors (17), providing a precondition for effective telomerase-dependent virotherapy. In contrast to HCCs, in the liver of patients with chronic hepatitis or liver cirrhosis telomerase activity is only weakly activated in 8% and 24% of the cases and immunohistochemical investigations showed very low numbers of hTERT-positive hepatocytes (<0.5%) within these livers (17). Reconstitution of telomerase activity in those hepatocytes may be a consequence of liver regeneration in chronic liver injury. However, it seems unlikely that these cells are able to contribute significantly to an unwanted toxicity of hTERT-Ad, as they are evenly distributed as isolated single cells within the liver and therefore cannot facilitate effective viral spreading of hTERT-Ad. In contrast to normal liver tissue, the accumulation of telomerase-positive tumor cells in HCCs allows effective viral replication and spreading of hTERT-Ad within the tumor tissue, resulting in significant inhibition of tumor growth in our animal model.

Preclinical and clinical results suggest potentially synergistic interactions of replicating adenoviruses with chemotherapy, in particular using platinum-containing chemotherapy (32, 33). In addition, it has been shown that systemic chemotherapy in combination with intratumoral injection of an E1B-55k-deleted virus, dl1520 (ONYX-015), is well tolerated by patients with head and neck cancer (33) and also by patients with colorectal liver metastases after intravascular virus administration (34, 35). We recently showed that tumor-restricted replication of hTERT-Ad is more effective and more specific compared with ONYX-015 (22), providing a rationale for the multimodal therapy of HCC patients with hTERT-Ad and systemic chemotherapy or TRAIL therapy without expecting cumulative toxicities.

In our study, neither TRAIL or chemotherapy alone nor the combined treatment with both agents resulted in significant destruction of HCC cells. However, telomerase-dependent virotherapy proved to be highly effective in a synergistic manner when applied with chemotherapy and TRAIL and consequently overcame therapeutic resistance of HCC cells. The synergistic effects are explained by an effective down-regulation of Mcl-1 expression through hTERT-Ad that sensitizes HCC cells for TRAIL- and chemotherapy-mediated apoptosis. Recently, it has been shown that E1A expression provokes a DNA damage response that results in Mcl-1 elimination (36). In accordance with these observations in our study, only E1A-expressing adenoviruses but not adenoviral infection alone were capable to down-regulate Mcl-1 expression in HCC cells. These results emphasize the importance of telomerase-controlled E1A expression in hTERT-Ad for targeted therapy of hepatocellular carcinomas. Inhibition of Mcl-1 expression by RNA interference led to an elevated caspase-3 activity in Hep3B cells, whereas the changes of caspase-3 activity were not significant in Huh7 cells. However, siRNA-mediated down-regulation of Mcl-1 significantly enhanced caspase-3 activity after application of chemotherapy and TRAIL in both HCC cell lines, confirming that down-regulation of Mcl-1 alone is sufficient to explain synergistic effects observed with virotherapy. In agreement with these results, complementation of Mcl-1 significantly reduced caspase-3 activity in hTERT-Ad-transduced cells when exposed to subsequent apoptosis-inducing agents. Because it has recently been shown that Mcl-1 also mediates resistance to TRAIL or chemotherapy in other cancers, such as cholangiocarcinomas (37) and melanomas (38), virotherapy may be a valuable tool in other drug-resistant tumors to improve the outcome of the patients.

Because enhancement of adenoviral replication in tumor cells by chemotherapy may also explain the synergistic effects of virochemotherapy, we investigated the effect of doxorubicin on viral replication. In contrast to previous observations in other tumor cells (39), chemotherapy neither improved viral replication nor led to an improved release of viral particles by infected hepatoma cells. Therefore, we found no evidence in our experiments that progeny and distribution of the virotherapeutic vector was directly enhanced by chemotherapy.

In accordance with the results observed in cell culture experiments, telomerase-dependent virotherapy acted also highly synergistic with systemic chemotherapy in drug-resistant HCCs in vivo and resulted in significant tumor remission and vast tumor destruction. In contrast, we observed no significant synergistic effects when virotherapy was applied together with local injection of Ad-TRAIL into the tumors. Although hTERT-Ad supports replication and spreading of E1-deleted Ad-TRAIL in HCCs by providing E1 proteins in trans, heterogenous Ad-TRAIL distribution within the tumor nodules may account for the discrepancy of in vitro and in vivo results. In contrast to TRAIL administration, systemic chemotherapy can also inhibit proliferation of nonmalignant cells within the tumor nodule, such as fibroblasts and endothelial cells. Because nonmalignant cells within the HCCs impair replication and spreading of hTERT-Ad, unselective inhibition of cell growth by chemotherapy may additionally contribute to synergistic effects of virochemotherapy in vivo.

Multimodal strategies seem necessary to successfully treat drug-resistant tumors such as HCCs. In our study, we showed that telomerase-dependent virotherapy overcomes resistance of HCCs against TRAIL and chemotherapy by down-regulation of Mcl-1 expression. In a clinical situation, hTERT-Ad virotherapy can be done analogous to our animal experiments by needle injection into tumor tissues. However, intra-arterial delivery of hTERT-Ad seems a more appropriate strategy for virotherapy of multilocular liver tumors. Several studies showed that regional delivery of adenoviral vectors into the hepatic artery results in transduction of ~5% to 25% of cancer cells in different liver tumors models (40, 41). This degree of initial transduction could be a sufficient base level for effective intratumoral replication and spreading of hTERT-Ad. The applicability of hTERT-Ad, especially in multimodal antitumor strategies, requires besides evidence for enhanced efficacy convincing proof of clinical safety. The unaltered levels of transaminase activity as well as the lack of germ cell infection and stem cell toxicity even after systemic infection with high doses of hTERT-Ad suggest that even with combined virochemotherapy detrimental side effects in vivo can be excluded. Taking into account that local application of viral vectors results in considerably less systemic viral infection, substantial damage to telomerase-positive host cells is very unlikely. Consequently, virotherapy should be an attractive strategy to improve the therapeutic results of regional chemotherapy or chemoembolization of HCCs.


   Acknowledgments
 
Grant support: Wilhelm Sander Stiftung grant 98.046.3 and Deutsche Forschungsgemeinschaft grant KFO119/1-1.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   Footnotes
 
Note: T. Wirth and F. Kühnel contributed equally to this work.

Received 10/12/04. Revised 4/ 5/05. Accepted 5/27/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. El Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745–50.[Abstract/Free Full Text]
  2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907–17.[CrossRef][Medline]
  3. Kubicka S, Rudolph KL, Hanke M, et al. Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area. Liver 2000;20:312–8.[CrossRef][Medline]
  4. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224:47–54.[Abstract/Free Full Text]
  5. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429–42.[CrossRef][Medline]
  6. Zender L, Kock R, Eckhard M, et al. Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors. Gastroenterology 2002;123:608–18.[CrossRef][Medline]
  7. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [see comments]. Science 1996;274:373–6.[Abstract/Free Full Text]
  8. Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy [In Process Citation]. Nat Med 2000;6:1134–9.[CrossRef][Medline]
  9. Steinwaerder DS, Carlson CA, Otto DL, Li ZY, Ni S, Lieber A. Tumor-specific gene expression in hepatic metastases by a replication-activated adenovirus vector. Nat Med 2001;7:240–3.[CrossRef][Medline]
  10. Ramachandra M, Rahman A, Zou A, et al. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol 2001;19:1035–41.[CrossRef][Medline]
  11. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000;106:763–71.[Medline]
  12. Li Y, Yu DC, Chen Y, et al. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 2001;61:6428–36.[Abstract/Free Full Text]
  13. Matsubara S, Wada Y, Gardner TA, et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res 2001;61:6012–9.[Abstract/Free Full Text]
  14. Hallenbeck PL, Chang YN, Hay C, et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999;10:1721–33.[CrossRef][Medline]
  15. Takahashi M, Sato T, Sagawa T, et al. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol Ther 2002;5:627–34.[CrossRef][Medline]
  16. Park YM, Choi JY, Byun BH, Cho CH, Kim HS, Kim BS. Telomerase is strongly activated in hepatocellular carcinoma but not in chronic hepatitis and cirrhosis. Exp Mol Med 1998;30:35–40.[Medline]
  17. Kawakami Y, Kitamoto M, Nakanishi T, et al. Immuno-histochemical detection of human telomerase reverse transcriptase in human liver tissues. Oncogene 2000;19:3888–93.[CrossRef][Medline]
  18. Toshikuni N, Nouso K, Higashi T, et al. Expression of telomerase-associated protein 1 and telomerase reverse transcriptase in hepatocellular carcinoma. Br J Cancer 2000;82:833–7.[CrossRef][Medline]
  19. Huang TG, Savontaus MJ, Shinozaki K, Sauter BV, Woo SL. Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther 2003;10:1241–7.[CrossRef][Medline]
  20. Kim E, Kim JH, Shin HY, et al. Ad-mTERT-{delta}19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 2003;14:1415–28.[CrossRef][Medline]
  21. Lanson NA Jr, Friedlander PL, Schwarzenberger P, Kolls JK, Wang G. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res 2003;63:7936–41.[Abstract/Free Full Text]
  22. Wirth T, Zender L, Schulte B, et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 2003;63:3181–8.[Abstract/Free Full Text]
  23. Irving J, Wang Z, Powell S, et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther 2004;11:174–85.[CrossRef][Medline]
  24. Kawashima T, Kagawa S, Kobayashi N, et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004;10:285–92.[CrossRef][Medline]
  25. Ryan PC, Jakubczak JL, Stewart DA, et al. Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer. Cancer Gene Ther 2004;11:555–69.[CrossRef][Medline]
  26. Su CQ, Sham J, Xue HB, et al. Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase-positive cancer cells. J Cancer Res Clin Oncol 2004;130:591–3.[Medline]
  27. Zhang Q, Nie M, Sham J, et al. Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin gene. Cancer Res 2004;64:5390–7.[Abstract/Free Full Text]
  28. Zou W, Luo C, Zhang Z, et al. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene 2004;23:457–64.[CrossRef][Medline]
  29. Ganten TM, Haas TL, Sykora J, et al. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 2004;11 Suppl 1:S86–96.[CrossRef]
  30. Wodarz D. Viruses as antitumor weapons: defining conditions for tumor remission. Cancer Res 2001;61:3501–7.[Abstract/Free Full Text]
  31. Cech TR. Beginning to understand the end of the chromosome. Cell 2004;116:273–9.[CrossRef][Medline]
  32. Heise C, Lemmon M, Kirn D. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Clin Cancer Res 2000;6:4908–14.[Abstract/Free Full Text]
  33. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer [In Process Citation]. Nat Med 2000;6:879–85.[CrossRef][Medline]
  34. Reid T, Galanis E, Abbruzzese J, et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 2001;8:1618–26.[CrossRef][Medline]
  35. Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002;62:6070–9.[Abstract/Free Full Text]
  36. Cuconati A, Mukherjee C, Perez D, White E. DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev 2003;17:2922–32.[Abstract/Free Full Text]
  37. Taniai M, Grambihler A, Higuchi H, et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 2004;64:3517–24.[Abstract/Free Full Text]
  38. Thallinger C, Wolschek MF, Wacheck V, et al. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol 2003;120:1081–6.[CrossRef][Medline]
  39. Bernt KM, Steinwaerder DS, Ni S, et al. Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors. Cancer Res 2002;62:6089–98.[Abstract/Free Full Text]
  40. Anderson SC, Johnson DE, Harris MP, et al. p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus. Clin Cancer Res 1998;4:1649–59.[Abstract]
  41. Gerolami R, Cardoso J, Bralet MP, et al. Enhanced in vivo adenovirus-mediated gene transfer to rat hepatocarcinomas by selective administration into the hepatic artery. Gene Ther 1998;5:896–4.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
E. Ramakrishna, N. Woller, B. Mundt, S. Knocke, E. Gurlevik, M. Saborowski, N. Malek, M. P. Manns, T. Wirth, F. Kuhnel, et al.
Antitumoral Immune Response by Recruitment and Expansion of Dendritic Cells in Tumors Infected with Telomerase-Dependent Oncolytic Viruses
Cancer Res., February 15, 2009; 69(4): 1448 - 1458.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Wang, T. Chen, N. Zhang, M. Yang, B. Li, X. Lu, X. Cao, and C. Ling
Melittin, a Major Component of Bee Venom, Sensitizes Human Hepatocellular Carcinoma Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Activating CaMKII-TAK1-JNK/p38 and Inhibiting I{kappa}B{alpha} Kinase-NF{kappa}B
J. Biol. Chem., February 6, 2009; 284(6): 3804 - 3813.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Ying, C. Tu, H. Ying, Y. Hu, Q. He, and B. Yang
MSFTZ, a Flavanone Derivative, Induces Human Hepatoma Cell Apoptosis via a Reactive Oxygen Species- and Caspase-Dependent Mitochondrial Pathway
J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 758 - 765.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S.-H. Kim, M. S. Ricci, and W. S. El-Deiry
Mcl-1: A Gateway to TRAIL Sensitization
Cancer Res., April 1, 2008; 68(7): 2062 - 2064.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. W. Meng, S.-H. Lee, H. Dai, D. Loegering, C. Yu, K. Flatten, P. Schneider, N. T. Dai, S. K. Kumar, B. D. Smith, et al.
MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis: A MECHANISTIC BASIS FOR SORAFENIB (BAY 43-9006)-INDUCED TRAIL SENSITIZATION
J. Biol. Chem., October 12, 2007; 282(41): 29831 - 29846.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. E. Bilsland, A. Merron, G. Vassaux, and W. N. Keith
Modulation of Telomerase Promoter Tumor Selectivity in the Context of Oncolytic Adenoviruses
Cancer Res., February 1, 2007; 67(3): 1299 - 1307.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wirth, T.
Right arrow Articles by Kubicka, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wirth, T.
Right arrow Articles by Kubicka, S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online